What Are the Latest Technologies Used in the Management and Closed-Loop Follow-Up of Incidental Pulmonary Nodules?

Incidental pulmonary nodules are now a routine part of clinical practice. With the expansion of CT imaging, IPN programs and lung cancer screening, detection has become more consistent than ever before.

What remains difficult is everything that follows.

Managing nodules requires more than identifying them. It involves understanding risk, defining follow-up, tracking patients over time, and ensuring that recommended care is completed. As volumes increase, this becomes difficult to sustain through manual workflows alone.

Recent advances in technology are beginning to address this problem, not by changing how clinicians make decisions, but by improving how consistently those decisions are executed.

Current solutions used in pulmonary nodule management and closed-loop follow-up can be broadly grouped into five categories:

Each of these addresses a different gap in the care pathway.

The first wave of innovation in this space focused on improving detection.

AI-based detection systems analyze imaging data, primarily CT scans, to identify pulmonary nodules with high sensitivity. These systems are particularly helpful for small or subtle nodules that may be difficult to detect consistently, especially in high-volume settings.

However, in real-world practice, detection remains an ongoing challenge, particularly outside structured screening programs.

A large proportion of patients first enter the system through routine chest X-rays, where nodules can be subtle, overlapping with anatomical structures, or deprioritized in busy workflows. This is where variability is highest, and where clinically meaningful findings are most likely to be missed.

AI-based detection on chest X-rays is beginning to address this gap.

For example, solutions such as qXR act as a second reader on routine imaging, highlighting suspected nodules in the 6–30 mm range and bringing attention to findings that may otherwise go unnoticed. In real-world settings, this has translated into the ability to identify up to 94% of nodules that were initially missed, while operating at a sensitivity of 83%, particularly for subtle findings in everyday clinical workflows1.

This is particularly relevant because chest X-rays are often the first imaging touchpoint, not just in screening but across emergency, outpatient, and inpatient settings. Improving detection at this stage effectively expands the front end of the pathway, allowing more patients to enter appropriate follow-up earlier.

At scale, this approach has already been implemented widely, with imaging AI systems deployed across 5,200+ sites and contributing to impacting over 43 million lives, reflecting both clinical adoption and real-world utility.

Detection technologies, therefore, are not just about improving sensitivity in controlled environments. They are about reducing variability in routine care, where the majority of patients are first seen.

Once a nodule is detected, the focus shifts to understanding its behavior over time.

Traditional measurement approaches rely on diameter, which can vary depending on technique and interpretation. Small differences in measurement can lead to uncertainty, particularly when assessing growth.

Volumetric analysis offers a more precise alternative.

By evaluating nodules in three dimensions, these tools allow clinicians to track changes in volume across serial scans. This is clinically important because growth is one of the strongest indicators of malignancy.

In practice, volumetric tools reduce inter-reader variability and provide a more reliable basis for comparing nodules over time. They also make it easier to detect subtle changes that may not be apparent through diameter measurements alone.

This shift from single timepoint assessment to longitudinal analysis is central to modern nodule management.

In real-world settings, this is increasingly supported by systems that combine quantitative measurement with longitudinal tracking. AI healthcare solutions such as qCT enable semi-automated nodule segmentation and provide standardized measurements across timepoints, including diameter, volume, and density. This allows clinicians to move beyond visual comparison and rely on reproducible metrics when assessing change.

An important addition is the ability to calculate volume doubling time (VDT) across serial scans, which provides a more objective indicator of growth dynamics. When combined with integrated clinical frameworks such as Lung-RADS classification, Brock risk scoring, and guideline-based follow-up recommendations, this creates a more structured approach to decision-making.

What this enables in practice is a shift from:

This level of precision becomes particularly important in cases where growth is subtle, and where small differences in interpretation can significantly influence management decisions.

Another important area of advancement is how findings are documented and communicated.

Radiology reports have traditionally been narrative, which can lead to variability in how nodules are described and how follow-up recommendations are conveyed.

Structured reporting systems aim to address this by integrating guideline-based frameworks, such as Lung-RADS or Fleischner, directly into reporting workflows.

Instead of relying solely on descriptive text, these systems provide:

This improves communication between radiologists and referring clinicians and reduces ambiguity in management decisions.

In practice, structured reporting helps ensure that recommendations are not only made, but are also actionable.

Even with improvements in reporting, a large amount of clinically relevant information remains embedded in unstructured text.

Natural language processing (NLP) has been used to extract information from radiology reports by identifying keywords and predefined patterns. These systems can detect mentions of nodules and capture basic attributes such as size or follow-up recommendations.

However, NLP approaches often struggle with variability in language and lack the ability to fully interpret clinical context. They may miss nuanced findings or incorrectly flag non-actionable mentions.

More recent approaches using large language models (LLMs) are beginning to address these limitations.

Unlike traditional NLP, LLM-based systems are designed to interpret meaning rather than simply extract terms. This allows them to:

In practical terms, this reduces the need for manual chart review and improves the accuracy of identifying patients who require follow-up.

The shift from NLP to LLM-based interpretation represents a move from pattern recognition to contextual understanding, which is particularly important in complex clinical narratives.

The most critical gap in nodule management has historically been follow-up over time.

Electronic medical records are effective at documenting care, but they are not designed to track patients longitudinally in a structured way. This creates a disconnect between recommendations and execution.

Longitudinal tracking systems are designed specifically to address this.

These platforms maintain a continuous view of patients with nodules, tracking:

More importantly, they introduce a time-based workflow, where patients are surfaced when action is required and missed follow-ups are flagged.

This transforms follow-up from a passive process into an actively managed one.

Studies have shown that a substantial proportion of patients with pulmonary nodules do not receive appropriate follow-up. Closed-loop systems are designed to reduce this gap by ensuring that patients remain within the pathway until follow-up is completed.

In practice, this is where dedicated tracking layers become essential. Platforms such as qTrack are designed to manage patients longitudinally across both screening and incidental findings, creating a single, unified view of follow-up. By bringing together imaging data, recommendations, real-time customizable dashboards and follow-up status into one workflow, these systems help ensure that patients do not fall out of the pathway between scans.

What this enables is not just tracking, but active coordination, where patients who require action are surfaced, prioritized, and managed in a structured way. For clinical teams, this reduces reliance on manual tracking and fragmented workflows, allowing follow-up to be handled more consistently at scale.

Individually, each of these technologies addresses a specific part of the problem.

The real value emerges when these layers are integrated.

Closed-loop systems bring these components together into a continuous workflow, where findings move from detection to follow-up without being lost in transition.

As imaging volumes continue to grow, maintaining this level of coordination manually becomes increasingly difficult.

qTrack is designed to support this infrastructure layer by providing longitudinal tracking across both screening and incidental findings. By maintaining visibility across imaging and time, and organizing patients within a structured workflow, these systems help ensure that recommended follow-up is completed.

This allows clinical teams to focus on interpretation and decision-making, while reducing gaps in execution.

The management of incidental pulmonary nodules is evolving.

The next phase of progress is not about detecting more nodules.  It is about managing them more reliably.

Advances in technology are enabling this shift by improving consistency, reducing variability, and ensuring that patients remain visible within the care pathway.

Ultimately, the goal is straightforward: every detected nodule should lead to appropriate, timely follow-up.